Beam Therapeutics Enters $500MM Financing Agreement with Sixth Street
Beam Therapeutics entered into a strategic financing agreement with Sixth Street for long-term, non-dilutive capital to fund the potential launch of ristoglogene autogetemcel (risto-cel) in sickle cell disease (SCD). The $500 million senior secured credit facility includes $100 million funded...
Read moreDetails










